Liraglutide for HIV-associated Neurocognitive Disorder
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
This study will test the effect of liraglutide on cognitive function in HIV-infected overweight or obese subjects with type 2 diabetes.
Condition or disease
HIV InfectionDiabetes Mellitus Type 2ObesityOverweightMetabolic Syndrome
HIV, insulin resistance and type 2 diabetes mellitus (DM) are independently associated with cognitive impairment. Considering the synergistic effects of HIV and DM on cognition, these subjects are at increased risk of cognitive impairment. glucagon-like peptide 1 (GLP-1) receptors have wide tissue distribution including the central nervous system. The study hypothesis is that GLP-1 could potentially ameliorate the impairments in cognition in this population. This study will assess the impact of liraglutide on neurocognitive performance and peripheral inflammatory markers. It will also evaluate the effects of liraglutide on glycemic control and metabolic risk factors in HIV infected subjects with type 2 diabetes.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
HIV controlled on therapy for at least 12 weeks
Viral load < 200 copies
BMI >27 to 45
Diagnosis of DM type 2 with A1-C >7 to 15
Participants must be willing to comply with all study related procedures
Personal or family history of pancreatitis
Medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2)
Allergy to liraglutide or any of the active ingredients in liraglutide or other GLP-1 analogue
Weight loss drugs other than metformin
Type 1 diabetes mellitus or diabetic ketoacidosis
Known major cognitive deficit dementia, history of head trauma with loss of consciousness >30 min, history of stroke, current central nervous system (CNS) disorder such as seizures or opportunistic CNS infection
Renal insufficiency defined as creatinine clearance < 60 mL/min
Active opportunistic infections
Pregnancy or breastfeeding
Unstable cardiovascular disease with hospitalization within 1 year for acute coronary syndrome
Decompensated heart failure
Active alcohol or opioid substitution therapy
Serious or unstable medical or psychological conditions that would compromise the subject's safety for successful participation